Search for: "Lisa Larrimore Ouellette"
Results 81 - 100
of 130
Sorted by Relevance
|
Sort by Date
5 Jun 2012, 9:46 am
See Lisa Larrimore Ouellette, Do Patents Disclose Useful Information? [read post]
20 Jan 2015, 12:12 pm
Luckily, Lisa Larrimore Ouellette, who runs Written Description, heard about my bloglessness and invited me to join her blog. [read post]
12 May 2020, 7:49 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceThe antiviral drug remdesivir, developed by California-based biopharmaceutical company Gilead Sciences in collaboration with government scientists, has emerged as the new standard of care for COVID-19 patients. [read post]
6 Oct 2014, 5:36 am
At Written Description, Lisa Larrimore Ouellette previews next week’s argument in Teva Pharmaceuticals v. [read post]
1 Jun 2017, 4:23 am
” At Stanford Law School’s Legal Aggregate blog, Lisa Larrimore Ouellette looks at the court’s decision inTC Heartland LLC v. [read post]
7 Apr 2020, 7:34 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowThe escalating pandemic has caused devastating shortages not only of ventilators and personal protective equipment like masks, but also of essential medicines needed to treat COVID-19 patients. [read post]
27 Apr 2020, 1:27 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowHealth systems worldwide are facing shortages of crucial medical supplies, including personal protective equipment (PPE), diagnostic testing components including kits and nasal swabs, and even ventilators or ventilator parts. [read post]
18 Dec 2020, 6:37 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsThe past two weeks have been full of exciting COVID-19 vaccine news, including the FDA’s emergency use authorizations (EUAs) for the Pfizer–BioNTech and Moderna vaccines and the nationwide rollout of Pfizer’s vaccine. [read post]
27 May 2020, 12:00 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
3 May 2021, 8:36 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceWe have written before about the challenges of making decisions under scientific uncertainty and the simultaneous importance and difficulty of developing high-quality clinical evidence under pandemic circumstances. [read post]
30 Nov 2020, 7:24 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceWhen President-elect Joe Biden is inaugurated in January, his administration will face the ongoing public health and economic challenges created by COVID-19. [read post]
3 Mar 2022, 6:43 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsSince the pandemic began, numerous recovered COVID-19 patients have reported having “long COVID”: COVID-19 symptoms persisting well beyond the underlying viral infection period. [read post]
30 Oct 2020, 12:50 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
27 Aug 2021, 12:18 pm
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn previous blog posts in this series, we have explored the roles different federal agencies, including the NIH, FDA, and CMS, play in the development and distribution of new healthcare technologies in the fight against COVID-19. [read post]
12 Oct 2020, 11:52 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsA recent STAT News report found that Operation Warp Speed—the government’s Manhattan Project-style effort to quickly develop a COVID-19 vaccine—has substantial military involvement. [read post]
18 Feb 2021, 10:24 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn our last post, we introduced some of the clinical evidence supporting the use of therapeutic antibodies against COVID-19—including Regeneron’s casirivimab and imdevimab and Eli Lilly’s bamlanivimab—and analyzed the existing problems in the distribution and administration of those therapies. [read post]
30 Jul 2020, 3:39 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
3 Jun 2021, 8:56 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsRecently, Pfizer and BioNTech and Moderna announced that they are seeking full FDA approval for their mRNA COVID-19 vaccines—filing, in FDA parlance, a Biologics License Application (BLA). [read post]
14 Jan 2019, 2:40 am
(Incidentally, one of the most concise summaries I've ever read of the inconclusive empirical evidence regarding the costs and benefits of patents appears on pages 75-87 of Lisa Larrimore Ouellete's article, Patent Experimentalism.)To some degree, Biagioli's article has a lot in common with these prior articles, expressing skepticism about whether patents and IP, generally, bring benefits that are greater than the costs, and about how society justifies the… [read post]
11 Jun 2020, 2:30 pm
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceOver the past two weeks, the United States—already hit hard by the COVID-19 pandemic—has reckoned with another public health crisis: police violence against Black Americans. [read post]
